A detailed history of Hazlett, Burt & Watson, Inc. transactions in Biogen Inc. stock. As of the latest transaction made, Hazlett, Burt & Watson, Inc. holds 37 shares of BIIB stock, worth $6,430. This represents 0.0% of its overall portfolio holdings.

Number of Shares
37
Holding current value
$6,430
% of portfolio
0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 30, 2024

BUY
$189.07 - $236.8 $6,995 - $8,761
37 New
37 $7,000
Q3 2023

Nov 02, 2023

BUY
$253.3 - $285.89 $6,332 - $7,147
25 Added 250.0%
35 $9,000
Q1 2023

Apr 27, 2023

BUY
$256.56 - $292.34 $2,565 - $2,923
10 New
10 $3,000

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $25B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Hazlett, Burt & Watson, Inc. Portfolio

Follow Hazlett, Burt & Watson, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hazlett, Burt & Watson, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Hazlett, Burt & Watson, Inc. with notifications on news.